Fenebrutinib

DB14785InvestigationalSmall molecule

Fenebrutinib is under investigation in clinical trial NCT03174041 (A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin).

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₃₇H₄₄N₈O₄ · 664.811 g/mol (avg)
Code names: GDC-0853

Resolves to

Compound

UNIIE9L2885WULCAS1434048-34-6ChEMBLCHEMBL4065122

Structure

InChIKeyWNEODWDFDXWOLU-QHCPKHFHSA-NSMILESC[C@H]1CN(CCN1C1=CC=C(NC2=CC(=CN(C)C2=O)C2=C(CO)C(=NC=C2)N2CCN3C4=C(CC(C)(C)C4)C=C3C2=O)N=C1)C1COC1

Targets

Q06187BTK

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fenebrutinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account